STORM Data Show Encouraging Responses, OS With Selinexor/Dexamethasone in Penta-Refractory Myeloma
Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.
Source: OncLive